Sharlene R. Lim, Ph.D. - Publications

Affiliations: 
2005 University of California, Irvine, Irvine, CA 
Area:
Molecular Biology

3/11 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2005 Madocsai C, Lim SR, Geib T, Lam BJ, Hertel KJ. Correction of SMN2 Pre-mRNA splicing by antisense U7 small nuclear RNAs. Molecular Therapy : the Journal of the American Society of Gene Therapy. 12: 1013-22. PMID 16226920 DOI: 10.1016/J.Ymthe.2005.08.022  0.6
2004 Lim SR, Hertel KJ. Commitment to splice site pairing coincides with A complex formation. Molecular Cell. 15: 477-83. PMID 15304226 DOI: 10.1016/J.Molcel.2004.06.025  0.6
2001 Lim SR, Hertel KJ. Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 3' splice site pairing. The Journal of Biological Chemistry. 276: 45476-83. PMID 11584013 DOI: 10.1074/Jbc.M107632200  0.6
Low-probability matches
2012 Lim SR, Qin X, Susser S, Nicholas JB, Lange C, Herrmann E, Hong J, Arfsten A, Hooi L, Bradford W, Nájera I, Smith P, Zeuzem S, Kossen K, Sarrazin C, et al. Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution. Antimicrobial Agents and Chemotherapy. 56: 271-9. PMID 22064535 DOI: 10.1128/AAC.05636-11  0.01
2011 Schaefer CJ, Kossen K, Lim SR, Lin JH, Pan L, Bradford W, Smith PF, Seiwert SD. Danoprevir monotherapy decreases inflammatory markers in patients with chronic hepatitis C virus infection. Antimicrobial Agents and Chemotherapy. 55: 3125-32. PMID 21502634 DOI: 10.1128/AAC.00131-11  0.01
2011 Nicholas J, Buckman B, Serebryany V, Schaefer C, Kossen K, Ruhrmund D, Hooi L, Aleskovski N, Arfsten A, Lim S, Pan L, Huang L, Rajagopalan R, Misialek S, Seiwert S. 1228 CHARACTERIZATION OF NOVEL, HIGHLY POTENT NS5A INHIBITORS WITH QD DOSING POTENTIAL AND ROBUST ACTIVITY IN AN HCV CHIMERIC ANIMAL MODEL Journal of Hepatology. 54: S485. DOI: 10.1016/S0168-8278(11)61230-0  0.01
2009 Buckman B, Kossen K, Ruhrmund D, Rajagopalan R, Stevens S, Hooi L, Snarskaya L, Wang T, Hong J, Lim S, Pan L, Huang L, Stoycheva N, Beigelman L, Seiwert S. 938 DISCOVERY OF POTENT, BIOAVAILABLE HCV NS3/4A INHIBITORS THAT DISPLAY UNIMPAIRED ACTIVITY AGAINST AN NS3 SEQUENCE VARIANT ASSOCIATED WITH RESISTANCE TO LINEAR TETRAPEPTIDES AND MACROCYCLIC INHIBITORS Journal of Hepatology. 50: S341. DOI: 10.1016/S0168-8278(09)60940-5  0.01
2008 Seiwert SD, Andrews SW, Jiang Y, Serebryany V, Tan H, Kossen K, Rajagopalan PT, Misialek S, Stevens SK, Stoycheva A, Hong J, Lim SR, Qin X, Rieger R, Condroski KR, et al. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrobial Agents and Chemotherapy. 52: 4432-41. PMID 18824605 DOI: 10.1128/Aac.00699-08  0.01
2007 Hummon AB, Lim SR, Difilippantonio MJ, Ried T. Isolation and solubilization of proteins after TRIzol extraction of RNA and DNA from patient material following prolonged storage. Biotechniques. 42: 467-70, 472. PMID 17489233 DOI: 10.2144/000112401  0.01
2007 Seiwert S, Hon J, Lim S, Wang T, Tan H, Blatt L. [647] SEQUENCE VARIATION OF NS3/4A IN HCV REPLICONS EXPOSED TO ITMN-191 CONCENTRATIONS ENCOMPASSING THOSE LIKELY TO BE ACHIEVED FOLLOWING CLINICAL DOSING Journal of Hepatology. 46: S244-S245. DOI: 10.1016/S0168-8278(07)62245-4  0.01
2000 Nasrallah ME, Kandasamy MK, Chang MC, Stadler Z, Lim S, Nasrallah JB. Identifying genes for pollen-stigma recognition in crucifers Annals of Botany. 85: 125-132. DOI: 10.1006/Anbo.1999.1039  0.01
Hide low-probability matches.